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Abstract
Avian influenza viruses, notably H5 subtype viruses, pose a continuous threat to public health due 
to their pandemic potential. In recent years, influenza virus H5 subtype split vaccines with novel 
oil-in-water emulsion based adjuvants (e.g. AS03, MF59) have been shown to be safe, 
immunogenic, and able to induce broad immune responses in clinical trials, providing strong 
scientific support for vaccine stockpiling. However, whether such vaccines can provide protection 
from infection with emerging, antigenically distinct clades of H5 viruses has not been adequately 
addressed. Here, we selected two AS03-adjuvanted H5N1 vaccines from the US national 
prepandemic influenza vaccine stockpile and assessed whether the 2004–05 vaccines could 
provide protection against a 2014 highly pathogenic avian influenza (HPAI) H5N2 virus (A/
northern pintail/Washington/40964/2014), a clade 2.3.4.4 virus responsible for mass culling of 
poultry in North America. Ferrets received two doses of adjuvanted vaccine containing 7.5 μg of 
hemagglutinin (HA) from A/Vietnam/1203/2004 (clade 1) or A/Anhui/1/2005 (clade 2.3.4) virus 
either in a homologous or heterologous prime-boost vaccination regime. We found that both 
vaccination regimens elicited robust antibody responses against the 2004–05 vaccine viruses and 
could reduce virus-induced morbidity and viral replication in the lower respiratory tract upon 
heterologous challenge despite the low level of cross-reactive antibody titers to the challenge 
H5N2 virus. This study supports the value of existing stockpiled 2004–05 influenza H5N1 
vaccines, combined with AS03-adjuvant for early use in the event of an emerging pandemic with 
H5N2-like clade 2.3.4.4 viruses.
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1. Introduction
Human infections with avian influenza A viruses are rare, but can occur in persons who have 
direct unprotected contact with infected birds or contaminated surfaces (Uyeki, 2009). 
Highly pathogenic avian influenza (HPAI) H5N1 virus are often associated with severe 
disease, multi-organ failure, and high mortality rates (Beigel et al., 2005; Tran et al., 2004). 
As of January 16, 2017, more than 850 cases of human infections with HPAI H5N1 viruses 
have been identified in several countries in Africa, Asia and Europe since their reemergence 
in 2003 (WHO, 2016a). Although no sustained human-to-human transmission of avian 
H5N1 viruses has been documented to date, the lack of population-level immunity in 
humans and the continuing evolution of H5 viruses provides the opportunity for the virus to 
adapt to humans and cause a pandemic (Webster and Govorkova, 2006).
Vaccines have proven to be effective measures to mitigate illness from human seasonal 
influenza infection, and the development of efficacious avian influenza vaccines has become 
an important component in pandemic preparedness (Wood, 2002). To date, several countries 
including the US have approved the production of a number of H5N1 influenza vaccines 
from candidate clade 1 and 2 viruses for human vaccination and stockpiling (SAGE Working 
Group on Influenza Vaccines and Immunizations, 2013). The available data from preclinical 
and clinical studies have shown that the influenza virus H5 subtype hemagglutinin (HA) is 
less immunogenic compared to similarly prepared human seasonal H1 or H3 HA, and that a 
higher HA dose or the use of adjuvant is necessary to overcome its low immunogenicity 
(Bresson et al., 2006; Nicholson et al., 2001; Stephenson et al., 2003). The highly diverse 
genetic nature and the rapid evolution of H5 viruses has resulted in the emergence of viruses 
with antigenic characteristics that are distinct from stockpiled vaccines. As the rapid 
generation of a well-matched vaccine would represent a challenging task at the onset of a 
pandemic, one important parameter in evaluating the efficacy of stockpiled vaccines is their 
ability to provide cross-clade protection to newly emerged strains of H5 influenza viruses.
In late 2014, HPAI H5N8 Eurasian lineage viruses (clade 2.3.4.4) were introduced into 
North America for the first time. This event led to the emergence of H5N2 and H5N1 
influenza viruses derived from the reassortment between HPAI H5N8 viruses and North 
American low-pathogenicity avian influenza viruses (Lee et al., 2016). The so-called H5Nx 
viruses (H5N8, H5N1 and H5N2) subsequently spread along the North American flyways 
for waterfowl, causing widespread poultry outbreaks and resulting in the culling of more 
than 40 million birds in the US alone (Krauss et al., 2016). Phylogenetic analysis showed 
that the H5Nx viruses from clade 2.3.4.4 are genetically distant from candidate H5 vaccine 
strain including A/Vietnam/1203/2004 (clade 1) and A/Anhui/1/2005 (clade 2.3.4) (Kwon et 
al., 2011). Although no human infections were reported in the US during H5Nx outbreaks in 
North America, 16 laboratory-confirmed cases of human infection including 6 deaths due to 
H5N6 virus from the same subclade have been reported to WHO from China since 2014 
(Shen et al., 2016; WHO, 2016b; Yang et al., 2015). The emergence of H5Nx influenza 
viruses has provided a unique opportunity to evaluate the efficacy of available stockpiled 
H5N1 vaccines against an antigenically distinct clade of H5 viruses. Here, we selected two 
stockpiled AS03-adjuvanted H5N1 influenza vaccines and assessed their protective 
effectiveness against newly emerged H5N2 virus challenge in the ferret model.
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2. Materials and methods
2.1. Vaccinations and Challenge
The Biomedical Advanced Research and Development Authority (BARDA)/US Department 
of Health and Human Services (HHS) provided the vaccines and adjuvant from the National 
Prepandemic Influenza Vaccine Stockpile. Influenza H5N1 subtype monovalent subvirion 
vaccines contained the HA and NA from A/Vietnam/1203/2004 (VN/04, HPAI, H5N1, clade 
1) (manufactured by Sanof Pasteur Ltd, Toronto, Canada) or A/Anhui/1/2005 (Anhui/05, 
HPAI, H5N1, clade 2.3.4) (manufactured by Seqirus Vaccines Limited, Speke, Liverpool, 
UK) virus. The stockpiled pre-pandemic H5N1 influenza virus vaccines were periodically 
tested under a formal stability program and the HA content of the influenza vaccines was 
measured by the single-radial-immunodiffusion (SRID) assay. Vaccines were mixed with 
AS03 adjuvant (GlaxoSmithKline Biologicals S.A., Rixensart, Belgium) in a 1:1 ratio 
immediately prior to vaccination according to manufacturer’s instructions. Eighteen male 
Fitch ferrets, 10 months of age (Triple F Farms, Sayre, PA) and serologically negative by 
hemagglutination-inhibition (HI) assay for currently circulating influenza viruses, were used 
in these studies. H5N1 vaccinations were conducted under BSL-2 conditions and H5N1 
virus challenges were performed in a biosafety level 3 containment laboratory with 
enhancements (BSL-3E) under the guidance of the Centers for Disease Control and 
Prevention’s Institutional Animal Care and Use Committee and the Select Agent Program 
(Chosewood LC, 2009). Ferrets were housed within a Duo-Flo Bioclean unit (Lab Products, 
Seaford, DE) with a maximum capacity of 18 ferrets. Two groups of 6 ferrets were 
vaccinated by the intramuscular route (i.m.) into the quadriceps muscle of the hind legs with 
two doses of AS03-adjuvanted vaccine (spaced 28 days apart) containing 7.5 μg of HA in 
0.5 ml of volume in either a homologous or heterologous prime-boost vaccination regime. 
For the homologous vaccination regime, two doses of Anhui/05 (Anhui/Anhui) vaccines 
were administered, and for the heterologous vaccination regime, VN/04 and Anhui/05 (VN/
Anhui) were administered as prime and boost vaccination, respectively. In ferrets, the AS03-
adjuvanted H5N1 split vaccines did not cause any detectable irritation or swelling at the 
injection site. Because it has been previously shown that animals that receive AS03 adjuvant 
only (without vaccine) do not elicit HI antibody titers and are not protected from influenza 
virus challenge (Baras et al., 2008; Leroux-Roels, 2009; Morel et al., 2011), PBS (0.5 ml) 
was used as the control in place of vaccine and adjuvant.
Baseline temperature and weight measurements were obtained before virus challenge. 
Temperatures were measured with a subcutaneous (s.c.) implantable temperature 
transponder (BioMedic Data Systems, Seaford, DE). On day 63 post-prime, all ferrets were 
challenged intranasally (i.n.) with 1 ml of 106.0 50% egg infectious dose (EID50) of A/
Northern pintail/Washington/40964/2014 (Pin/2014) (H5N2, clade 2.3.4.4) virus diluted in 
PBS as described previously (Pulit-Penaloza et al., 2015). Ferrets were monitored for 
changes in body temperature, weight loss, and the presence of clinical signs. To evaluate the 
effect of vaccination on viral replication in both the upper and lower respiratory tract, the 
presence of infectious virus was determined in nasal washes collected on days 2 and 3 post-
challenge (p.c.), and in nasal turbinate, trachea, and lung tissues collected on day 3 p.c. 
following ferret necropsy. Titers of infectious virus in the abovementioned samples were 
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expressed as EID50/ml or g and calculated by the method of Reed and Muench (Reed LJ, 
1938) following serial titration in eggs as described previously (Maines et al., 2005).
2.2. Humoral and cell-mediated immune responses
Antibody titers from sera collected on 28 days post-prime as well as 7 and 28 days post-
boost vaccination were determined by microneutralization (MN) assay (WHO, 2011) and a 
modified HI assay with horse red blood cells, shown to possess higher sensitivity in 
detecting antibody responses against H5 influenza viruses compared to MN assay (Levine et 
al., in press). Sera were initially treated with receptor-destroying enzyme (RDE) from Vibrio 
cholerae (Denka Seiken, Tokyo, Japan) overnight at 37 °C. The enzyme was then inactivated 
at 56 °C for 30 min, and PBS was added to the sera for a final dilution of 1:10. Ferret sera 
were tested for MN and HI antibody titers against the following H5 viruses: Pin/2014 
(H5N2), Anhui/05, and A/Vietnam/1194/2004 (VN/1194; H5N1), the latter of which is an 
antigenically related surrogate virus for the detection of anti-VN/04 antibodies.
To measure total HA binding antibodies induced by vaccination, the flu antibody biosensor 
assay (f-AbBA) was performed with biolayer interferometry (BLI) technology on an Octet 
Red instrument (Pall ForteBio, CA) as described previously (Carney et al., 2010). In brief, 
recombinant HA (rHA) of influenza VN/04 (H5N1) and Pin/2014 (H5N2) were generated 
and purified following procedures as described previously (Stevens et al., 2006; Yang et al., 
2016). The rHA proteins were successfully expressed, trimeric proteins were assessed and 
purified using analytical size exclusion chromatography (SEC). The rHA for Anhui/05 was 
obtained from International Reagent Resource (IRR, Manassas, VA). rHA was bound to 
anti-penta-His biosensors by incubating the tip of biosensors in solutions of rHA (25 μg/ml) 
in ForteBio’s kinetics buffer with the usage of a sidekick biosensor immobilization station 
(Pall ForteBio, CA). RDE-treated ferret sera collected at 28 days post boost were serially 
diluted in two-fold increments beginning at 1:80 with kinetics buffer and their association/
disassociation to rHA was analyzed by incubating the tip of rHA-loaded biosensors into 
diluted sera. Data were analyzed using the system software and the result was presented as 
shifted wavelength (nm) at the end of the association step.
To measure cell-mediated immunity (CMI), ferret peripheral blood leukocytes were 
stimulated overnight with positive control (PMA/ionomycin), negative control (allantoic 
fluid, or no stimulation), or with recombinant HA from Anhui/05, VN/04, or Pin/2014 virus, 
in the presence of Golgi-blocker for the last 6 h. The cells were then permeabilized, stained 
with anti-ferret CD4 (Sino Biological Inc, Beijing, China), anti-human CD8 (OKT8; 
eBioscience, Hatfield, UK), and anti-bovine interferon gamma (“IFNγ”) (MorphoSys, AbD 
Serotec, Oxford, UK), and analyzed by flow cytometry (Reber et al. submitted). A response 
in which more than 0.1% of cells expressed IFNγ was considered positive.
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3. Results
3.1. AS03-adjuvanted H5N1 vaccines are efficient at inducing HI and MN antibody 
responses
The immunogenicity of the H5N1 influenza vaccines was assessed by HI and MN assays. 
We found that two doses of AS03-adjuvanted H5N1 vaccine delivered in either a 
homologous (Anhui/Anhui) or heterologous (VN/Anhui) prime-boost regimen were 
necessary to induce adequate antibody responses to the vaccine viruses (Fig. 1). A 
homologous boost with Anhui/05 adjuvanted vaccine (Group 1) substantially enhanced the 
immune response against the Anhui/05 vaccine virus, as the HI (Fig. 1A) and MN (Fig. 1B) 
geometric mean titers (GMT) increased from 27 and 12 before boost to 427 (95% 
confidence interval [CI]=144–1270) and 329 (81–1338), respectively, on day 7 post-boost (7 
d-p.b). Antibody titers dropped slightly by 28 days post-boost (28 d-p.b) with HI and MN 
GMT of 127 (21–985) and 201 (53–766), respectively. Furthermore, two doses of Anhui/05 
adjuvanted vaccine also elicited a moderate cross-clade antibody response to the A/VN/
1194/2004 (clade 1) virus, which shares high HA sequence similarity with the VN/04 
vaccine virus. Here, Anhui/Anhui vaccination resulted in peak HI and MN titers to VN/1194 
virus of 57 (11–293) and 19 (5–80), respectively, on day 7 post boost, declining less than 
two-fold by day 28 post boost.
For the heterologous (VN/Anhui) prime-boost group (Group 2), an Anhui/05 vaccine boost 
following VN/04 prime not only induced potent antibody responses to Anhui/05 virus, but 
also enhanced antibody responses against the priming vaccine virus, VN/04 (Fig. 1). The 
ferrets from this group exhibited a peak HI GMT of 143 (35–585) and 90 (28–288) against 
priming VN/04 and booster Anhui/05, respectively on day 7 post boost (Fig. 1A). HI titers 
remained at 63 (35–115) and 80 (32–201) against Anhui/05 and VN/04, respectively on day 
28 post boost. In general, the MN titers from the heterologous VN/Anhui vaccination group 
were slightly lower than HI titers with peak GMT of 53 and 50 against the priming and 
boosting virus strains, which declined to 20 and 40, respectively, on day 28 post boost (Fig. 
1B).
In addition to measuring HI and neutralizing specific antibodies induced by vaccination, we 
also assessed the total HA binding antibodies with the f-AbBA assay, in which antibody 
binding to HA-coated biosensor tips results in an increase of biosensor tip thickness that can 
be measured as shifted wavelength (nm). As shown in Fig. 1C, on 28 days post boost both 
the homologous (Anhui/Anhui) and heterologous (VN/Anhui) vaccination induced a 
significantly higher (p < 0.01) level of Anhui/05 HA binding antibodies compared to PBS 
control groups. Interestingly, compared to homologous vaccination, heterologous (VN/
Anhui) vaccination induced higher total HA binding antibodies to all three antigens tested, 
(Anhui/05, VN/04, and Pin/2014), although only the differences in responses to Anhui/05 
and VN/04 antigens reached statistical significance (p < 0.05).
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3.2. Protective efficacy of stockpiled H5N1 influenza virus vaccines against clade 2.3.4.4 
(H5N2) virus challenge
Next, we evaluated the cross-reactivity of both vaccination regimens against the Pin/2014 
(H5N2) virus from clade 2.3.4.4. We found that both homologous and heterologous 
vaccination regimes elicited relatively low levels of antibody responses to Pin/2014 virus; 
only 2/6 and 3/6 ferrets from homologous and heterologous vaccine groups, respectively, 
exhibited an HI titer ≥40 at peak response (Fig. 1A). A ≥40 titer in humans has been 
associated with an approximately 50% reduction in infection with seasonal influenza viruses 
(Baz et al., 2013; Potter and Oxford, 1979) and is considered to be a seroprotective titer, but 
it is unknown if this titer cutoff represents a comparable correlate of protection for H5 
viruses. Both vaccination approaches also induced low levels of cross-clade binding 
antibodies to recombinant Pin/2014 HA; heterologous prime-boost induced slightly higher 
HA-binding antibodies than those from homologous prime-boost animals (Fig. 1C). 
Although we detected low levels of HI and HA-binding antibodies to Pin/2014 virus, we did 
not detect cross-reactive MN antibodies against the H5N2 virus (Fig. 1B). Taken together, 
we conclude that homologous vaccination with two doses of Anhui/05 (clade 2.3.4) vaccine 
or heterologous vaccination primed with VN/04 (clade 1) followed by boost with Anhui/05 
(clade 2.3.4) can elicit sufficient antibody responses (HI titer ≥40) against the H5N1 vaccine 
strains. However, both vaccination regimens induced only limited cross-reactive antibody 
responses against the Pin/2014 H5N2 virus with ≤50% seroprotective rates based on HI 
titers, confirming that the recently emerged H5Nx viruses are antigenically divergent from 
candidate vaccine strains from clade 1 and clade 2.3.4 (Levine et al., in press).
To evaluate the cross-protective efficacy of H5N1 vaccination, all three groups of ferrets 
were challenged with the heterologous Pin/2014 (H5N2) virus and subjected to post-mortem 
necropsy on day 3 p.c. for collection of tissues throughout the respiratory tract. As 
characterized previously, HPAI Pin/2014 virus was not lethal in ferrets, but the virus 
exhibited enhanced virulence compared to another 2014 North American clade 2.3.4.4 virus, 
A/gyrfalcon/Washington/41088/2014 (H5N8) virus (Pulit-Penaloza et al., 2015). 
Unvaccinated ferrets from the PBS control group (Gr-3) reached a mean maximum weight 
loss of 10% on day 3 p.i. Conversely, Anhui/Anhui and VN/Anhui vaccinated groups lost 
only 4.3% and 2.3% of their pre-challenge body weight, respectively, which was 
significantly lower compared to the control ferrets (p < 0.05, by one-way ANOVA with 
Dunett post-test). Ferrets from all three groups shed comparable amounts of infectious virus 
(approximately 104.0 EID50/ml) on days 2 and 3 p.c. in nasal washes (NW) and exhibited 
similar viral titers in nasal turbinates (NT) on day 3 p.c. (Fig. 2). However, differences in 
viral titers were observed in trachea and lung tissues. High viral loads (average titer of 104.8 
EID50/g) were detected in both the trachea and lungs of unvaccinated control ferrets. In 
contrast, only 1 of 6 (103.4 EID50/g) and 2 of 6 (103.0, 104.0 EID50/g) ferrets from the Anhui/
Anhui and VN/Anhui vaccinated groups, respectively, possessed low viral titers in the 
trachea, and only 2 of 6 ferrets (102.2, 103.6 EID50/g) from Anhui/Anhui group and 1 of 6 
(102.3 EID50/g) from VN/Anhui group possessed detectable virus in the lung (Fig. 2). Thus, 
compared to the unvaccinated control group, viral titers in the trachea and lungs of both 
vaccinated groups were reduced by over 100-fold, which achieved significance compared to 
unvaccinated ferrets (p < 0.001). Collectively, we found that either homologous prime-boost 
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Anhui/05 vaccination or heterologous prime-boost with VN/04 and Anhui/05 vaccination 
could protect ferrets from H5N2 virus challenge by reducing viral morbidity as measured by 
weight loss, and viral replication in the lower respiratory tract of ferrets.
4. Discussion
Producing and stockpiling H5N1 vaccines has been an important part of pandemic 
preparedness efforts. Human H5N1 vaccines are available in the US federal vaccine 
stockpile (https://www.medicalcountermeasures.gov/barda.aspx) and may provide protection 
against a newly emerging H5 pandemic virus before a strain-specific vaccine becomes 
available. However, the level of cross-protection of these stockpiled vaccines against 
antigenically distinct H5 subtype viruses is poorly understood. Here, we determined whether 
AS03-adjuvanted stockpiled 2004–05 H5N1 influenza virus vaccines provide cross-
protection against the more recently emerged H5N2 clade 2.3.4.4 virus challenge in ferrets. 
AS03 is an oil-in-water emulsion consisting of squalene, alpha-tocopherol, and 
polysorbate-80 and has been shown to be well tolerated in laboratory animals and humans 
(Segal et al., 2015). AS03 has been shown to significantly enhance serum HI titers to 
candidate pre-pandemic influenza vaccines and allows for antigen sparing (Leroux-Roels et 
al., 2007, 2008). The robustness of antibody responses elicited by AS03-adjuvanted H5N1 
vaccines demonstrated that our ferret model is in good agreement with previous data from 
human clinical trials, in which two doses of adjuvanted A/Vietnam/1194/2004, clade 1 
vaccine containing 3.8 μg of HA could induce > 82% seroprotective rates in humans aged 
18–60 (Leroux-Roels et al., 2007, 2008). Moreover, Langley et al. showed that AS03 
formulated with split VN/1194 inactivated virus induced sufficient immune responses in 
adults with as few as two doses of 3.75 μg of HA (Langley et al., 2010). Importantly, we 
found in this study that despite low cross-reactive antibody responses to the challenge Pin/
2014 virus, both vaccination regimens could reduce virus-induced morbidity and viral 
replication in the respiratory tract of ferrets following challenge with the antigenically 
distant H5N2 virus from clade 2.3.4.4.
The heterologous prime-boost vaccine group was included in the study because this strategy 
can induce broader cross-reactive antibodies (Galli et al., 2009; Khurana et al., 2014; Lu, 
2009). Levine et al. recently showed that heterologous, but not homologous prime-boost 
vaccination with VN/1194 and an adjuvanted Anhui/05 stockpiled H5N1 vaccine induced 
modest cross-reactive HI antibody to Pin/2014 H5N2 virus (Levine et al., in press). The 
study also showed that the 2004–05 H5N1 vaccine and 2014 H5N2 viruses are antigenically 
distinct from each other; ferret sera to Anhui/05 (H5N1) reacted with Pin/2014 (H5N2) virus 
at titers that were > 16-fold lower than titers against homologous virus. In the current study, 
serum HI GMT titers to Pin/2014 virus following heterologous prime-boost were slightly 
higher than those from homologous prime-boost animals; however, the improved cross-
reactivity to the clade 2.3.4.4 H5N2 virus was not statistically significant. Based on previous 
data from human clinical trials, the length of the interval between priming and boosting 
affects the magnitude of the immune response to vaccination, and a heterologous booster 
given 6 months after priming can induce higher immune responses compared to two doses of 
vaccines given 28 days apart (Belshe et al., 2011). In the current study, we studied the most 
rapid sequence of prime and boost (28 days apart) to emulate what may occur during a 
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pandemic. Further investigation is warranted to ascertain whether longer intervals of 
heterologous boost after initial prime would improve cross-immune response to 
antigenically distant H5 viruses.
Protection was likely due to cross-reactive HA antibodies, which were detected by both f-
AbBA and HI assays. The 2004–05 influenza H5N1 vaccines containing the N1 NA shares 
only 43–45% amino acid identity with the NA protein of Pin/2014 (H5N2) virus. Therefore, 
the protection induced by the AS03-adjuvanted H5N1 vaccines makes it unlikely to be due 
to cross-reactive responses to viral antigens on the N1 NA. In accord with our findings, a 
recent study with alumadjuvanted inactivated whole H5N1 vaccines prepared using the 
recombinant H5 viruses from clade 1, 2.2 and 2.5 also demonstrated strong protection from 
the H5N8 clade 2.3.4.4 virus challenge in both mouse and ferret models (Park et al., 2016). 
Although cross-reactive antibody levels to Pin/2014 virus were low, the generation of HI 
titers ≥10 against the H5N2 virus likely played a role in decreasing virus replication in 
trachea and lung tissues. Previous vaccine studies have shown that at antibody titers as low 
as 10 or 20 are sufficient to confer protection in ferrets (Mahmood et al., 2008; Pearce et al., 
2012), suggesting that the HI titer threshold of 40 (titer ≥1:40), considered to be protective 
for H3N2 virus in humans (Baz et al., 2013), may not hold true for all subtypes and species. 
Other immunological mechanisms may also have contributed to the cross-clade protection 
against H5N2 virus. Studies have suggested that both cell-mediated immunity and non-
neutralizing antibodies, such as antibodies with antibody-dependent cell-mediated 
cytotoxicity (ADCC) activity, contribute to cross-clade protection in the absence of a 
detectable neutralizing antibody response (Lipatov et al., 2006; Santiago et al., 2011). 
ADCC assays measure HA-binding, non-neutralizing antibodies and thus it is conceivable 
that non-neutralizing antibodies from vaccinated ferrets in our current study confer 
protection against H5N2 virus through the ADCC pathway. However, ADCC activity has 
been difficult to establish in some species due to the requirement of species-specific 
functional effector cells that mediate ADCC such as natural killer (NK) cells, monocytes, or 
macrophages. To understand the immunologic basis of protection against heterologous 
challenge, we attempted to test whether ADCC activity accounted for the cross-protection 
observed in ferrets. Although our laboratory has recently developed an improved ADCC NK 
cell activation assay utilizing human NK cell lines as effector cells (Zhong et al., 2016), the 
assay failed to detect H5-specific ADCC titers in ferret sera, most likely due to the 
incompatibility of the ferret immunoglobulin Fc region with human NK cell FcγRIIIa 
receptor (unpublished observation).
To further explore the role of cell-mediated protection in the setting of heterologous 
challenge, T cell responses following vaccination were additionally examined. However, 
only very low levels of IFN-γ-producing CD4+ and CD8+ T cells from leukocytes prepared 
from peripheral blood samples on days 7 and 28 post-boost were detected upon stimulation 
with the recombinant HA proteins from Anhui/05, VN/04 or Pin/2014 viruses; no significant 
difference among three groups were observed (data not shown). Overall, the ferret CMI 
responses were too low to draw conclusions regarding cross-reactivity. Future studies 
pertaining to ferret cell-mediated immunity may require the development of ferret specific 
reagents to better understand the immunology associated with vaccine protection, in 
particular cross-protectiveness of H5 vaccines.
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As currently circulating H5Nx viruses continue to diverge from vaccine strains, there is a 
heightened need to assess the efficacy of stockpiled vaccines against newly emergent H5 
viruses with pandemic potential. Our study provides evidence for the broad cross-
protectiveness of two existing stockpiled H5N1 vaccines, which have been evaluated in 
clinical trials and proven to be highly immunogenic (Belshe et al., 2014; Bresson et al., 
2006). Altogether, we conclude that current split H5N1 vaccines for stockpiling or 
inactivated whole virus vaccines remain useful tools in pandemic preparedness.
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Fig. 1. Ferret antibody responses following AS03-adjuvanted H5N1 vaccination
Ferret serum samples collected at 28 days post prime vaccination (28 d-p.p), 7 days post 
boost (7 d-p.b), and 28 days post boost (28 d-p.b) were pretreated with receptor-destroying 
enzyme (RDE) and tested by HI and MN assays against A/Anhui/1/2005, A/Vietnam/
1194/2004, and A/Northern pintail/2014 viruses for determination of antibody responses. HI 
antibody titers (A) and MN antibody titers (B) are shown as GMT with 95% CI. The 
detection limit (5) is shown with a dashed line. Serum samples with antibody titers below 
the detection limit were assigned values of 5 for purposes of GMT calculations. (C) For the 
measurement of total binding antibodies to recombinant HA’s, ferret sera collected on day 
Sun et al. Page 12
Virology. Author manuscript; available in PMC 2018 January 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28 post boost were RDE-treated and serially diluted in two-fold increments before binding 
to recombinant HA coated biosensor tips. The shifted wavelength (nm) resulted from the 
binding of 80-fold diluted ferret serum samples to the recombinant HA’s are shown as the 
mean plus standard deviation. Statistical analysis was performed using two-way ANOVA 
with GraphPad prism, ***, p < 0.001 and *p < 0.05.
Sun et al. Page 13
Virology. Author manuscript; available in PMC 2018 January 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. Viral replication in ferret respiratory tract samples following heterologous virus challenge
Groups of six ferrets were administered two doses of homologous (Anhui/Anhui) or 
heterologous (VN/Anhui) AS03-adjuvanted H5 split vaccines or PBS, and challenged 
intranasally with the Pin/2014, H5N2 clade 2.3.4.4 virus. Nasal washes were collected on 
days 2 and 3 post challenge. On day 3 post challenge, ferrets were euthanized to collect 
nasal turbinates, trachea and lung tissues. Viral titers are shown as mean plus standard 
deviation. The limit of detection of 1.5 log10EID50/ml [nasal wash, nasal turbinate] or g 
[trachea, lung]) was indicated with a dashed line. Tissue samples with viral titers below the 
detection limit were assigned values of 1.5 log10EID50/ml or g for purposes of calculating 
mean titers. Titers are indicative of 6 ferrets unless specified otherwise. Statistical analysis 
was performed using two-way ANOVA with GraphPad Prism, ***, p < 0.001.
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